Key facts
- It has raised $9.1M.
- Notable investors include MedTech Innovator, European Commission, BioTools Innovator, HCVC, Austria Wirtschaftsservice — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Sarcura
- ·The full record, as it builds
Funding rounds
No funding rounds for Sarcura are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sarcura
Developer of a device platform designed to enable autonomous and miniaturized cell therapy manufacturing. The company's platform offers semiconductor-based microfluidics, intelligent batch processing, and modular system architecture, enabling cell therapy manufacturers to reduce costs, increase production capacity, and tailor processes for diverse cell types.
- Sector
- Healthcare
- HQ
- Klosterneuburg, Austria
- Founded
- 2019
- Employees
- 24
- Website
- sarcura.com/
- Ownership
- Privately Held (backing)
Sarcura doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sarcura shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sarcura in its N-PORT filings yet. We sweep new filings monthly.